Trophos Report issue

For profit Phase 2 Phase 3
Founded: Marseille France (1999)
Status: Acquired by Roche (2015)

Organization Overview

First Clinical Trial
2007
NCT00496457
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Trophos, Parc Scientifique de Luminy - Case 931, Luminy Biotech Enterprises, 13288 Marseille Cedex9 - France

Active Ingredients

Drugs in Phase 3 Trials (1)

Olesoxime (3 trials)

Drugs in Phase 2 Trials (1)

tro40303 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Amyotrophic Lateral Sclerosis (Phase 3)

Diabetic Neuropathies (Phase 2)

Infarction (Phase 2)

Motor Neuron Disease (Phase 3)

Myocardial Infarction (Phase 2)

Peripheral Nervous System Diseases (Phase 2)

Reperfusion Injury (Phase 2)

Sclerosis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 2